# MetaVia Inc.: financial statements, quarterly

MTVA · Nasdaq · CIK 1638287 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mtva.md) · [Financials](/companies/mtva/financials.md) · [Filings](/companies/mtva/filings.md) · [Insiders](/companies/mtva/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mtva/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | not reported | not reported | not reported | [8.1](/filings/0001558370-25-010759.md) | [4.5](/filings/0001104659-25-107726.md) | [4.1 d](/filings/0001104659-26-034911.md) | [2.3](/filings/0001104659-26-061166.md) | [2.3](/filings/0001104659-26-092051.md) | [1.9](/filings/0001104659-25-107726.md) | [0.2 d](/filings/0001104659-26-034911.md) | [2.1](/filings/0001104659-26-061166.md) | [3.5](/filings/0001104659-26-092051.md) |
| Operating income | $m | [(3.9)](/filings/0001558370-24-014863.md) | [(5.7) d](/filings/0001558370-25-003386.md) | [(6.9)](/filings/0001558370-25-007749.md) | [(10.1)](/filings/0001558370-25-010759.md) | [(6.3)](/filings/0001104659-25-107726.md) | [(5.6) d](/filings/0001104659-26-034911.md) | [(3.9)](/filings/0001104659-26-061166.md) | [(4.3)](/filings/0001104659-26-092051.md) | [(3.5)](/filings/0001104659-25-107726.md) | [(2.0) d](/filings/0001104659-26-034911.md) | [(4.0)](/filings/0001104659-26-061166.md) | [(5.4)](/filings/0001104659-26-092051.md) |
| Income tax | $m | [0.0](/filings/0001558370-24-014863.md) | [0.0 d](/filings/0001558370-25-003386.md) | [0.0](/filings/0001558370-25-007749.md) | [0.0](/filings/0001558370-25-010759.md) | [0.0](/filings/0001104659-25-107726.md) | [0.0 d](/filings/0001104659-26-034911.md) | [0.0](/filings/0001104659-26-061166.md) | [0.0](/filings/0001104659-26-092051.md) | [0.0](/filings/0001104659-25-107726.md) | [0.0 d](/filings/0001104659-26-034911.md) | [0.0](/filings/0001104659-26-061166.md) | [0.0](/filings/0001104659-26-092051.md) |
| Net income | $m | [(3.8)](/filings/0001558370-24-014863.md) | [(5.3) d](/filings/0001558370-25-003386.md) | [(6.7)](/filings/0001104659-25-107726.md) | [(10.1)](/filings/0001104659-25-107726.md) | [(5.7)](/filings/0001104659-25-107726.md) | [(5.2) d](/filings/0001104659-26-034911.md) | [(3.7)](/filings/0001104659-26-092051.md) | [(4.0)](/filings/0001104659-26-092051.md) | [(3.4)](/filings/0001104659-25-107726.md) | [(1.9) d](/filings/0001104659-26-034911.md) | [(3.8)](/filings/0001104659-26-092051.md) | [(5.3)](/filings/0001104659-26-092051.md) |
| Diluted EPS | $ per share | [(0.75)](/filings/0001558370-24-014863.md) | not reported | [(1.32)](/filings/0001558370-25-007749.md) | [(1.85)](/filings/0001558370-25-010759.md) | [(0.55)](/filings/0001104659-25-107726.md) | not reported | [(3.93)](/filings/0001104659-26-061166.md) | [(2.87)](/filings/0001104659-26-092051.md) | [(0.14)](/filings/0001104659-25-107726.md) | not reported | [(0.79)](/filings/0001104659-26-061166.md) | [(0.90)](/filings/0001104659-26-092051.md) |
| Basic EPS | $ per share | [(0.75)](/filings/0001558370-24-014863.md) | not reported | [(1.32)](/filings/0001558370-25-007749.md) | [(1.85)](/filings/0001558370-25-010759.md) | [(0.55)](/filings/0001104659-25-107726.md) | not reported | [(3.93)](/filings/0001104659-26-061166.md) | [(2.87)](/filings/0001104659-26-092051.md) | [(0.14)](/filings/0001104659-25-107726.md) | not reported | [(0.79)](/filings/0001104659-26-061166.md) | [(0.90)](/filings/0001104659-26-092051.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [25.8](/filings/0001558370-23-018842.md) | [22.4](/filings/0001558370-25-003386.md) | [16.0](/filings/0001558370-24-007479.md) | [27.9](/filings/0001558370-24-012272.md) | [21.7](/filings/0001558370-24-014863.md) | [16.0](/filings/0001104659-26-034911.md) | [11.2](/filings/0001558370-25-007749.md) | [17.6](/filings/0001558370-25-010759.md) | [14.3](/filings/0001104659-25-107726.md) | [10.3](/filings/0001104659-26-092051.md) | [13.7](/filings/0001104659-26-061166.md) | [12.6](/filings/0001104659-26-092051.md) |
| Current assets | $m | [26.1](/filings/0001558370-23-018842.md) | [22.5](/filings/0001558370-25-003386.md) | [16.8](/filings/0001558370-24-007479.md) | [28.5](/filings/0001558370-24-012272.md) | [21.9](/filings/0001558370-24-014863.md) | [16.1](/filings/0001104659-26-034911.md) | [12.0](/filings/0001558370-25-007749.md) | [18.3](/filings/0001558370-25-010759.md) | [14.6](/filings/0001104659-25-107726.md) | [10.9](/filings/0001104659-26-092051.md) | [14.2](/filings/0001104659-26-061166.md) | [13.1](/filings/0001104659-26-092051.md) |
| Total assets | $m | [26.4](/filings/0001558370-23-018842.md) | [22.8](/filings/0001558370-25-003386.md) | [17.0](/filings/0001558370-24-007479.md) | [28.8](/filings/0001558370-24-012272.md) | [22.1](/filings/0001558370-24-014863.md) | [16.3](/filings/0001104659-26-034911.md) | [12.1](/filings/0001558370-25-007749.md) | [18.5](/filings/0001558370-25-010759.md) | [14.8](/filings/0001104659-25-107726.md) | [11.1](/filings/0001104659-26-092051.md) | [14.4](/filings/0001104659-26-061166.md) | [13.3](/filings/0001104659-26-092051.md) |
| Current liabilities | $m | [4.7](/filings/0001558370-23-018842.md) | [6.0](/filings/0001558370-25-003386.md) | [6.8](/filings/0001558370-24-007479.md) | [9.7](/filings/0001558370-24-012272.md) | [9.1](/filings/0001558370-24-014863.md) | [8.3](/filings/0001104659-26-034911.md) | [7.7](/filings/0001558370-25-007749.md) | [8.8](/filings/0001558370-25-010759.md) | [8.4](/filings/0001104659-25-107726.md) | [5.6](/filings/0001104659-26-092051.md) | [5.2](/filings/0001104659-26-061166.md) | [6.3](/filings/0001104659-26-092051.md) |
| Total liabilities | $m | [4.9](/filings/0001558370-23-018842.md) | [6.1](/filings/0001558370-25-003386.md) | [6.9](/filings/0001558370-24-007479.md) | [9.8](/filings/0001558370-24-012272.md) | [9.2](/filings/0001558370-24-014863.md) | [8.3](/filings/0001104659-26-034911.md) | [7.7](/filings/0001558370-25-007749.md) | [8.8](/filings/0001558370-25-010759.md) | [8.4](/filings/0001104659-25-107726.md) | [5.8](/filings/0001104659-26-092051.md) | [5.3](/filings/0001104659-26-061166.md) | [6.4](/filings/0001104659-26-092051.md) |
| Shareholders' equity | $m | [21.6](/filings/0001558370-24-014863.md) | [16.7](/filings/0001104659-26-034911.md) | [10.1](/filings/0001104659-25-107726.md) | [18.9](/filings/0001104659-25-107726.md) | [13.0](/filings/0001104659-25-107726.md) | [7.9](/filings/0001104659-26-092051.md) | [4.4](/filings/0001104659-26-092051.md) | [9.6](/filings/0001104659-26-092051.md) | [6.3](/filings/0001104659-25-107726.md) | [5.3](/filings/0001104659-26-092051.md) | [9.1](/filings/0001104659-26-092051.md) | [6.8](/filings/0001104659-26-092051.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,814) d](/filings/0001558370-24-014863.md) | [(3,393) d](/filings/0001558370-25-003386.md) | [(6,442)](/filings/0001558370-25-007749.md) | [(7,251) d](/filings/0001558370-25-010759.md) | [(5,548) d](/filings/0001104659-25-107726.md) | [(5,469) d](/filings/0001104659-26-034911.md) | [(4,815)](/filings/0001104659-26-061166.md) | [(3,071) d](/filings/0001104659-26-092051.md) | [(2,955) d](/filings/0001104659-25-107726.md) | [(4,860) d](/filings/0001104659-26-034911.md) | [(4,258)](/filings/0001104659-26-061166.md) | [(3,762) d](/filings/0001104659-26-092051.md) |
| Capital expenditure | $k | [37.0 d](/filings/0001558370-24-014863.md) | [9.0 d](/filings/0001558370-25-003386.md) | [5.0](/filings/0001558370-25-007749.md) | [3.0 d](/filings/0001558370-25-010759.md) | [0.0 d](/filings/0001104659-25-107726.md) | [0.0 d](/filings/0001104659-26-034911.md) | not reported | not reported | [0.0 d](/filings/0001104659-25-107726.md) | [0.0 d](/filings/0001104659-26-034911.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.9](/filings/0001558370-23-018842.md) | [5.1](/filings/0001558370-24-007479.md) | [5.1](/filings/0001558370-24-012272.md) | [5.1](/filings/0001558370-24-014863.md) | [5.1](/filings/0001558370-25-007749.md) | [5.4](/filings/0001558370-25-010759.md) | [10.2](/filings/0001104659-25-107726.md) | [0.9](/filings/0001104659-26-061166.md) | [1.4](/filings/0001104659-26-092051.md) | [24.4](/filings/0001104659-25-107726.md) | [4.9](/filings/0001104659-26-061166.md) | [5.9](/filings/0001104659-26-092051.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 6,588,101 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001104659-26-092051.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.